Kornimate/medical-research-clean huggingface dataset:
reactogenicity, immunogenicity and inflammatory response by new covid-19 vaccine platforms

Conditions: COVID-19 Vaccination; Inflammation; Vaccine Immune Response; Vaccine Adverse Reaction

Summary: analysis of humoral antibody and cytokine kinetics after vaccination with either bnt162b2 or chadox1 ncov-19 vaccine and factors influencing the vaccine immunogenicity

there is a different aspect of reactogenicity between bnt162b2 and chadox1 ncov-19 vaccine. both new platform vaccines were concerned if they would elicit more significant local or systemic reactogenicity compared to the conventional vaccines. previous studies had reported that immune cells such as mast cells and macrophages are activated just after vaccination, and release proinflammatory cytokines such as interleukin (il)-6 and tumor necrosis factor (tnf)-α. the post-vaccination kinetics of inflammatory cytokines would be variable by each vaccine platform, and might be associated with reactogenicity. it is an interesting issue to be investigated whether the reactogenicity following newly developed bnt162b2 and chadox1 would be associated with immunogenicity and inflammatory response or not. to better clarify these uncertainties, we evaluated the change of antibody response between bnt162b2 and chadox1 over three months post-vaccination, in relation to the kinetics of inflammatory cytokines and reactogenicity.

Eligibility criteria:
inclusion criteria: * volunteers who provide the informed consent after either bnt162b2 or chadox1 vaccination * healthy adults without underlying medical condition exclusion criteria: * volunteers who had ever infected with sars-cov2 were excluded.

Keywords: reactogenicity; immunogenicity
mapping of lymph node metastasis and survival for pn+ superficial esophageal squamous cell carcinoma

Conditions: National Cancer Center/Cancer Hospital

Summary: with the deeper tumor invasion, the higher lnm rate beside the bilateral recurrent laryngeal nerves(rln) was.


Eligibility criteria:
inclusion criteria: * our predefined search strategy identified pt1n+ escc cases without preoperative treatment, between february 2012 and april 2022. exclusion criteria: * the patients were excluded because they were (1)less than 10 lymph nodes removed; (2) lacked specific sites of lnm; or (3) incomplete follow-up information.
prostate health index for prostate cancer diagnosis

Conditions: Prostate Cancer

Summary: prostate biopsies are the gold standard for prostate cancer (pca) diagnosis. they are performed according to the results of the measurement of prostate-specific antigen (psa) in the serum of patients with pca suspicion. more than half of the prostate biopsies reveal eventually negative because of the poor specificity of prostate-specific antigen assay. the prostate health index (phi) is a new diagnostic tool that has been described as a good predictor of prostate biopsy outcome. no large study has been performed so far in france. this study aim to evaluate prostate health index diagnostic performances in a large multicentric french cohort of patients undergoing prostate biopsies because of clinical and/or biological suspicion of prostate cancer. prostate health index will be measured in patients directed to prostate biopsies according to usual practices. inclusion of 400 patients within 6 months in 12 french centers is expected. the ability of prostate health index to predict prostate cancer at biopsy will be evaluated in terms of intrinsic and extrinsic diagnostic performances including sensitivity, specificity, predictive values, diagnostic accuracy, area under receiver operating curves and decision curve analyses.


Eligibility criteria:
inclusion criteria: * man ≥ 18 years old * addressed for prostate biopsy because of serum total prostate specific antigen ≥ 4 ng/ml and/or abnormal digital rectal examination and/or first degree familial history of prostate cancer * agreeing to participate to the study exclusion criteria: * personal history of positive prostate biopsy (evidence of prostate cancer) * personal history or evidence of prostate cancer based on clinical data (highly suspicious digital rectal examination (≥ct3) and/or serum total psa ≥ 20 ng/ml and/or evidence for lymph node or bone metastases (retroperitoneal lymph nodes, bone lesions ...) * evidence for synchronous non-prostate cancer (current active treatment) * adult protected by law
a study of trastuzumab emtansine (t-dm1) in combination with docetaxel, and potentially pertuzumab, in participants with advanced breast cancer

Conditions: Breast Cancer

Summary: this is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of t-dm1 plus docetaxel for the treatment of participants with metastatic breast cancer (mbc) and of t-dm1 plus docetaxel with or without pertuzumab, for the treatment of participants with locally advanced breast cancer (labc). the study comprises an initial dose finding (feasibility) part to determine the maximum tolerated dose (mtd) of t-dm1 and docetaxel, followed by an extension part aiming to consolidate the safety and efficacy of the recommended docetaxel/t-dm1 combination regimen.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0-1 (ecog performance status of 2 will be allowed if only due to debilitating bone disease) * her2-positive metastatic or locally advanced breast cancer for mbc participants: * documented metastatic or inoperable locally advanced (without meeting labc criteria) disease, amenable for treatment with docetaxel * history of disease progression within 3 months prior to study entry for labc participants: * newly diagnosed locally advanced breast cancer, stage iia-iiic (american joint committee on cancer \[ajcc\] staging system) exclusion criteria: * significant cardiac disease * inadequate bone marrow, liver or renal function for mbc participants: * participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases * brain metastases that are untreated, symptomatic or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment. for labc participants: * clinically or radiologically detectable metastasis (m1 disease) * participants for whom surgery as primary intent procedure is the best option to treat their disease * participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease
fsu hypertension self-care training study

Conditions: Hypertension

Summary: the purpose of this study is to compare the effectiveness of two forms of self-care training on the overall health of adults with hypertension.

the fsu college of social work and the department of psychology are seeking adults age 25 and older with a clinical diagnosis of hypertension for a randomized trial using willpower to manage high blood pressure. voluntary participants will complete three phases: baseline, intervention, and post-treatment. baseline phase includes a preliminary phone screening, fasting blood draw, physiological test (measuring heart rate variability, chest compression, etc.), and a psychosocial inventory. intervention phase includes 8 weeks of once weekly trainings (approximately one hour long) to be held on a weekday evening. participants will be randomly assigned to one of the two willpower groups and will be asked to rehearse the willpower method at least once daily for 30 minutes during these 8 weeks. post-treatment phase includes two follow-up booster sessions (at week 12 and week 16) for refreshing willpower techniques, a follow-up fasting blood draw, a physiological test, and a psychosocial inventory. participation is completely voluntary and confidential. volunteers completing each of the phases will be compensated $100 for their time. if someone is interested in participating, they should call our office at 850-645-0247 or email fsuwillpower@gmail.com.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension * age 25 or older exclusion criteria: * pregnancy * participation in other clinical trials or drug/behavioral treatment * previously participated in any other clinical trials/training on health-related behavior (tai-chi, yoga, nutritional education, yoga class) * kidney disease * cancer/chemotherapy, advanced hiv/aids, severe liver disease * severe ischemic heart disease (unstable angina, hospitalization for heart attack, coronary revascularization) * congestive heart failure * severe inflammatory/rheumatologic disorders (severe arthritis) * severe mental health diagnosis such as schizophrenia or bi-polar disorder * occurrence of any neurological disorders such as stroke or dementia * addicted to any legal/illegal drugs or alcohol without at least 1 year of sobriety * any infectious conditions such as pneumonia, traumatic wound, or surgery that may cause inflammation in the past 14 days

Keywords: hypertension high blood pressure willpower self care
optimal attained ldl-cholesterol levels in patients who achieved ≥50% ldl reduction after pci

Conditions: Coronary Artery Disease; Hyperlipidemias

Summary: for the management of low-density lipoprotein-cholesterol (ldl-c), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in ldl-c levels. high-intensity or maximally tolerated intensity can be maintained without a target goal. however, the european guideline recommends less than 55 mg/dl of ldl-c after pci.

to investigate the optimal attained ldl-c levels in patients who achieved ≥50% ldl-c reduction after pci.

Eligibility criteria:
inclusion criteria: * patients receiving pci with health check up before and after pci within 3 years exclusion criteria: * patients receiving statin before pci * patients with liver cirrhosis * patients with cancer * patients without prescription of statin * patients with ldl-c \<55 mg/dl before pci

Keywords: percutaneous coronary intervention statin
a study of paramedic hf management

Conditions: Heart Failure

Summary: the purpose of this research is to see if having community paramedic (cp) visit patients at home to manage their heart failure help them stay out of the hospital and improve their overall health compared to standard care. the investigators want to find out if their approach is better for patients in terms of their quality of life, hospital stays, emergency visits, and cost. the investigators are also looking to see how happy patients and doctors are with this method and if it's a practical and sustainable option for the future.


Eligibility criteria:
inclusion criteria: one of the following criteria: 1. adults admitted to the hospital with decompensated hf eligible for early discharge with cp support and monitoring. 2. acutely decompensated hf patients at home or being evaluated in the ambulatory clinic who require large volume diuresis but do not require hospital-level monitoring. 3. stage d advanced hf patients who require frequent (\>weekly) diuretic adjustments (either inpatient or outpatients). exclusion criteria: 1. hospital-level monitoring or care is clinically indicated. 2. failed safety assessment, active substance abuse, or behavioral health diagnosis which could impact participation. 3. enrolled in hospice. 4. patient is a resident in a skilled nursing facility. 5. patient does not have a primary care physician or cardiologist at mayo clinic. 6. patient participants with communication barriers due to medical illness or cognitive impairment. 7. pregnant
investigation of the effects of online education application on gynecological cancer patients receiving chemotherapy

Conditions: Gynecological Cancer

Summary: the aim of the study was to examine the effect of online nursing education given to women diagnosed with gynecological cancer and receiving chemotherapy. it was conducted as a randomized controlled experimental study. the study examined the effect of online nursing education given to patients in the intervention group diagnosed with gynecological cancer and receiving chemotherapy on symptoms, quality of life and patient satisfaction. the control group received routine nursing care.

this study examined the effect of online nursing education given to women diagnosed with gynecological cancer and receiving chemotherapy. this randomized controlled experimental study was conducted in a public hospital in balıkesir province between december 1, 2021 and june 1, 2024. the study sample consisted of 90 women (intervention=45, control=45). online nursing education was given to women in the intervention group receiving chemotherapy. patients in the control group received routine nursing care. the study used the women's descriptive characteristics questionnaire, disease and treatment questionnaire, european organization for research and treatment of cancer quality of life questionnaire, nightingale symptom assessment scale, nurse follow-up form and patient satisfaction questionnaire. data were collected during three chemotherapy cycles in four phases.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with gynecological cancer and who have started chemotherapy treatment for the first time in the hospital, having gynecological cancer receiving chemotherapy speak turkish, have no communication problems, accept voluntarily to participate in the study, patients who are 18 years of age or older exclusion criteria: * illiterate patients who do not have a smart phone or computer patients who receive radiotherapy together with chemotherapy patients who do not know they have been diagnosed with cancer

Keywords: gynecological cancer symptom management telenursing quality of life chemotherapy
effect of dry needling on myofascial trigger point

Conditions: Pain

Summary: myofascial trigger point is one of the most common causes of musculoskeletal disorders. myofascial trigger point in upper trapezius has been reported as a symptom in patients with neck and upper thoracic pain. the purpose of this study was to investigate the prolonged effect of dry needling on myofascial trigger point in upper trapezius muscle.

pain intensity and disability of arm, hand and shoulder (dash) were collected at base line and at the end of treatment sessions, two weeks and three months follow up in both groups.

Eligibility criteria:
inclusion criteria: * 1. presence of a palpable taut band in muscle. * 2. presence of a hypersensitive tender spot in the taut band. * 3. reproduction of the typical referred pain pattern of the mtp in response to compression. to detect active trps, trp pressure tolerance was assessed using a mechanical pressure algometer. the investigator applied continuous pressure with the algometer with an approximate pressure of 2.5 kg/cm2. * 4. spontaneous presence of the typical referred pain pattern and/or patient recognition of the referred pain as familiar. * 5- pain of at least 30 mm on a visual analogue scale (vas). the selected mtp of the ut muscle was located in the middle of the more nearly horizontal fibers of the ut 40. exclusion criteria: * had a history of fibromyalgia syndrome, whiplash injury, cervical spine surgery and fracture, cervical radiculopathy, having therapy within the past month before the study * any systematic disease such as rheumatism and tuberculosis or cervical myelopathy, multiple sclerosis * local infection, * pregnancy * taking anticoagulants (e.g. warfarin) * long-term steroid using

Keywords: dry needling, myofascial trigger point, upper trapezius
orathecin + gemcitabine versus placebo + gemcitabine in chemonaive non-resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: patients will be treated with gemcitabine and orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. toxicity of the drug combination will also be evaluated.


Eligibility criteria:
inclusion criteria: * the patient is at least 18 years of age. * the patient has histologically or cytologically confirmed, non-resectable, stage ii-iv primary adenocarcinoma of the pancreas. * the patient has had a baseline computed tomography (ct) scan, or magnetic resonance imaging (mri), to evaluate tumor(s) within 28 days prior to randomization. * the patient has never been treated with prior chemotherapy, with the exception of low-dose 5-fluorouracil (5-fu) as a radiation sensitizer. * the patient has sufficiently recovered from the effects of previous surgery (no less than 3 weeks prior to randomization), radiotherapy, and/or immunotherapy (no less than 4 weeks prior to randomization). * the patient's estimated life expectancy is at least 12 weeks. * the patient has a karnofsky performance status between 50 and 100. * the patient has adequate bone marrow function. * the patient has adequate hepatic and renal function. exclusion criteria: * the patient has any active, uncontrolled infection requiring antibiotics. * the patient has any serious, uncontrolled concomitant systemic disorder. * the patient has surgery scheduled within 8 weeks following initiation of treatment. * the patient is pregnant or nursing. * the patient is not capable of consistent oral intake of at least 3 l/day of fluid and/or requires constant intravenous (iv) hydration or frequent tube feeding. * the patient is receiving any investigational agent(s) or has been a participant in a clinical trial within the last 30 days.

Keywords: rubitecan orathecin 9-nitrocamptothecin gemcitabine gemzar pancreatic cancer adenocarcinoma rfs 2000
effect of non-invasive photobiomodulation therapies in patients with trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: the aim of this study was to compare the effectiveness of two different photobiomodulation (pbm) therapies as an alternative to medical treatment to reduce pain and improve quality of life in patients with trigeminal neuralgia (tn).

the aim of this study was to compare the effectiveness of two different photobiomodulation (pbm) therapies as an alternative to medical treatment to reduce pain and improve quality of life in patients with trigeminal neuralgia (tn). a total of 45 patients with mean age of 46.09 years (26 female, 19 male) were randomly divided into three groups. the first group received pbm therapy with a new generation diode laser (ngd laser). in the second group, low-level nd:yag laser was applied along the affected nerve line and the placebo group received the same protocol with nd:yag laser without the device switched on. the scores were recorded before and after the treatment using the brief pain inventory-facial (bpi-facial) scale.

Eligibility criteria:
inclusion criteria: * patients diagnosed with idiopathic trigeminal neuralgia as defined by the international headache society (2). * patients diagnosed with idiopathic trigeminal neuralgia and receiving medical treatment (carbamazepine, etc.) * patients with unilateral, severe, sudden onset of facial pain along the branches of the trigeminal nerve. * patients who have not previously received any interventional treatment for tn. * patients recently diagnosed and started on a first dose of carbamazepine and its derivatives exclusion criteria: * • patients diagnosed with type 2 (atypical, symptomatic) trigeminal neuralgia as defined by the international headache society (2). * patients with etiologies such as tumour, multiple sclerosis or neurovascular compression on radiography. * pregnant women * patients with systemic diseases such as diabetes, cardiovascular disease, hypertension, etc. * patients who have been previously diagnosed and treated with any type of tn therapy.
identification of risk factors for cardiovascular disease and cancer in korean population: a prospective cohort study

Conditions: Cardiovascular Diseases; Malignancy; Risk Factor

Summary: cancer and cardiovascular disease are the global leading causes of death. these two disease entities are multifactorial disease that are caused by several factors. the aim of this prospective cohort study was to investigate the status of risk factors profiles and health related behavior in korean population, and to discover novel risk factors associated with the occurrence of endpoint events.

this is a single center, observational, prospective cohort study. the primary outcomes include the incidence of mace (major adverse cardiovascular events) and the incidence of any malignancy. we plan to collect the baseline information at enrollment and the occurrence of clinical endpoint events will be followed for at least 10 years. the study will enroll 510,000 subjects aged ≥19 years who underwent a general health screening in korea.

Eligibility criteria:
inclusion criteria: * men or women aged 19 years and older who underwent a general health screening at the health promotion center of ulsan university hospital (ulsan, korea) * subjects have to agree to participate by signing a consent exclusion criteria: * subjects who cannot or reject to sign the consent form.

Keywords: cardiovascular disease malignancy risk factor
a study to assess zd6474 (zactima™) monotherapy in locally advanced or metastatic hereditary medullary thyroid cancer

Conditions: Thyroid Cancer

Summary: this will be a phase ii, open label study to establish the effect of once-daily oral doses of zd6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options * aged 18 or over and a life expectancy of more than 12 weeks exclusion criteria: * the last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy * congenital long qt syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia

Keywords: medullary thyroid cancer mtc hereditary medullary thyroid cancer thyroid cancer
open-label safety and tolerability of oxymorphone ir and er in opioid tolerant pediatric subjects

Conditions: Chronic Pain

Summary: patients will convert from current opioid to oxymorphone er and undergo titration. during the titration period, subjects will receive daily oxymorphone extended release tablets(s) every 12 hours. dosing adjustments will be based on the review of the subject's pain scores. oxymorphone ir 5 mg will be provided to be used as supplemental "breakthrough" pain medication (as needed). titration period will end when the fixed dose of study medication is tolerated and the subject achieves adequate analgesia. subjects will then proceed to the open-label 3-month maintenance period on the fixed dose of study medication established during the titration period.

an open-label safety and tolerability study of immediate-release and extended-release oxymorphone in opioid-tolerant pediatric subjects with chronic pain.

Eligibility criteria:
inclusion criteria: * have chronic cancer or non-cancer pain, currently requiring treatment of pain with a strong opioid for at least 5 days (3 of 5 days at a dose greater than or equal to 45 mg/daily (qd) oral morphine equivalent) * weigh at least 50 kg * expected to continue to require a strong opioid for pain relief for at least 4 weeks and up to 4 months. exclusion criteria: * have a life expectancy \<4 weeks * plan to undergo a surgical procedure within 3 days of study entry or during the titration period * have dysphagia or difficulty swallowing whole tablets * have a previous exposure to oxymorphone * have an ileostomy

Keywords: opioid tolerant pediatric male 6-17 years of age female 6-17 years of age pain non malignant malignant